Why AstraZeneca (AZN) Stock Fell Despite Crushing Q1 Earnings Expectations

Key Takeaways

Table of Contents

First-quarter revenue reached $15.29B, surpassing the $14.94B consensus forecast
Core earnings per share of $2.58 exceeded analyst projections of $2.54
Oncology division revenues climbed 16% compared to last year; rare disease segment increased 15%
Company reaffirmed annual outlook: mid-to-high single-digit revenue expansion, low double-digit core EPS improvement
Shares declined approximately 1% following the announcement, with market watchers noting expectations were already embedded in valuations

AstraZeneca delivered impressive first-quarter numbers on Wednesday, yet investors responded with a collective yawn. The British pharmaceutical giant reported quarterly revenue of $15.29 billion, climbing from $13.59 billion in the same period last year and exceeding Wall Street’s $14.94 billion projection.

AstraZeneca $AZN Q1 revenue rose to $15.29B, above the $14.94B estimate, as strong cancer and rare-disease drug sales lifted results. Oncology now makes up about 44% of revenue. Core EPS was $2.58 vs. $2.54 est., and the company kept full-year guidance.

— Wall St Engine (@wallstengine) April 29, 2026

The company’s core earnings per share landed at $2.58, topping analyst expectations of $2.54. Core operating income expanded 12% to reach $4.25 billion.

Even with these positive results, AZN shares dropped roughly 1% during early London market hours. According to eToro analyst Adam Vettese, the tepid response reflected that traders had already factored the pharmaceutical company’s strong performance into current valuations.

AstraZeneca PLC, AZN

The oncology segment continues serving as the company’s powerhouse, representing 44% of total revenue. This division posted a 16% year-over-year increase at constant exchange rates, generating $6.8 billion.

Imfinzi, a treatment for bladder and lung cancers, soared 30% to reach $1.7 billion. Tagrisso, targeting lung cancer patients, climbed 5% to $1.8 billion. Enhertu, addressing breast and gastric cancers, exploded 34% higher to $831 million.

The company’s rare disease business unit also posted solid performance, with revenues advancing 15% year-over-year.

Oncology and Specialty Treatments Fuel Growth

American market revenue expanded 10% during the quarter, while Chinese sales edged up 2%. AstraZeneca has executed significant strategic initiatives in both territories recently, including a $50 billion U.S. manufacturing commitment and a $15 billion investment pledge in China.

The pharmaceutical company also obtained a New York Stock Exchange listing and secured exemption from U.S. tariffs through a drug pricing arrangement.

First-quarter net income increased to $3.08 billion compared to $2.92 billion during the prior-year period.

Development Pipeline and Long-Term Vision Remain Intact

Chief Executive Pascal Soriot restated the organization’s ambitious goal of achieving $80 billion in annual revenue by 2030. He indicated that AstraZeneca is gearing up for numerous product introductions and maintains its trajectory toward more than 20 new market entries by that timeframe.

Three new medications could receive U.S. market authorization this year subject to regulatory clearance: baxdrostat for hypertension treatment, camizestrant for specific breast cancer types, and gefurulimab for a chronic autoimmune condition.

The company left its full-year 2026 projections untouched. AstraZeneca anticipates mid-to-high single-digit revenue expansion and low double-digit core earnings per share growth measured in constant currencies.

Last week, Soriot cautioned that Europe faces becoming merely a “sales office” for the pharmaceutical sector as it lags behind America and China in competitiveness. This backdrop explains AstraZeneca’s continued efforts to expand its presence in both major markets.

Financial analysts at LSEG project full-year 2026 sales growth of 7.2% and earnings growth of 11.2%, closely matching 2025 performance levels.

AstraZeneca’s shares have traded sideways throughout the year leading up to today’s earnings release. The better-than-expected results did little to alter that trajectory.

✨ Limited Time Offer